EP Patent

EP0818198A1 — Potentiation of drug response by increasing serotonin availability

Assigned to Lilly SA · Expires 1998-01-14 · 28y expired

What this patent protects

The power of fluoxetine, venlafaxine and duloxetine to increase the availability or serotonin is augmented by administration in combination with WAY 100635.

USPTO Abstract

The power of fluoxetine, venlafaxine and duloxetine to increase the availability or serotonin is augmented by administration in combination with WAY 100635.

Drugs covered by this patent

milnacipran-hydrochloride (MILNACIPRAN HYDROCHLORIDE)

Patent Metadata

Patent number: EP0818198A1
Jurisdiction: EP
Classification: —
Expires: 1998-01-14
Drug substance claim: No
Drug product claim: No
Assignee: Lilly SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.